scholarly journals Investigation of Epstein-Barr Virus Antibodies by Chemiluminescent Microparticle Immunoassay Method in Patients of Different Age Groups: Evaluation of Atypical Serological Profiles

2021 ◽  
pp. 1-6
Author(s):  
Alev Çetin Duran ◽  
Tuğba Kula Ati
Keyword(s):  
Epstein Barr Virus ◽  
Acute Infection ◽  
Age Groups ◽  
Igg Antibodies ◽  
Serological Tests ◽  
Past Infection ◽  
Barr Virus ◽  
Serological Profile ◽  
Chemiluminescent Microparticle Immunoassay ◽  
Epstein Barr

Objective: Epstein-Barr virus (EBV) can cause different clinical pictures from infectious mononucleosis (IM) to malignancies such as B-cell lymphomas, Burkitt’s lymphoma, nasopharyngeal carcinoma, and Hodgkin lymphoma. VCA-IgM, VCA-IgG, EBNA-1 IgG antibodies are the most commonly used antibodies in revealing the serological profile. This study aimed to examine the serological profiles of patients with suspected EBV infection and to interpret the atypical profiles encountered. Methods: The results of VCA-IgM, VCA-IgG, and EBNA-1 IgG antibodies studied in the Microbiology Laboratory between 2017-2019 were evaluated retrospectively. EBV serological tests (VCA-IgM, VCA-IgG, and EBNA-1 IgG) were performed according to the manufacturer’s recommendations using the chemiluminescent microparticle immunoassay (CMIA) method (Architect, Abbott, Wiesbaden, Germany). Results: Of the 2486 patients evaluated, 1341 (53.9%) were male, 1145 (46.1%) were female, and the average age was determined as 16.93 ± 19.5. EBV past infection was detected in 56.65% of the cases, the acute infection was detected in 17.25%, and 21.09% did not encounter EBV. Atypical serological profile was detected in 5.01%. As an atypical profile, the most common positivity of three antibodies together (3.90%), then isolated VCA-IgG positivity (0.91%), and isolated EBNA-1 IgG positivity (0.20%) were determined. It was determined that 24.24% of the cases with an atypical profile were immunosuppressive patient.  Conclusions: The rate of encountering EBV in our study is 78.91%. The atypical EBV serological profile rate was found to be 5.01%. Approximately one-fourth of the cases with an atypical profile was found to be in the patient group with immune disorders. It is thought that antibody tests are not sufficient to determine the stage of infection, especially in these patient groups, and further tests should be performed. It has been demonstrated that serological monitoring is required for the interpretation of atypical profiles. Keywords: Epstein-Barr virüs, serological tests, chemiluminescent microparticle immunoassay (CMIA), atypical serological profile

scholarly journals Correlation between results of PCR and specific serological tests in diagnosis of Epstein-Barr virus in patients with mononucleosis syndrome

2009 ◽  
Vol 56 (3) ◽  
pp. 71-76
Author(s):  
A.V. Banko ◽  
I.B. Lazarevic ◽  
M.D. Cupic ◽  
A.M. Knezevic ◽  
G.D. Stevanovic ◽  
...  
Keyword(s):  
Epstein Barr Virus ◽  
Laboratory Diagnosis ◽  
Final Diagnosis ◽  
Serological Testing ◽  
Active Infection ◽  
Serological Tests ◽  
Past Infection ◽  
Barr Virus ◽  
Ebv Dna ◽  
Epstein Barr

Routine laboratory diagnosis of infectious mononucleosis is based on EBV serological testing, but due to problems in interpretation of results, molecular methods, especially PCR, are often necessary. The aim of the present study was to investigate correlation between results of PCR and specific serological tests in diagnosis of Epstein-Barr virus in patients with mononucleosis syndrome. The study comprised 68 patients with mononucleosis syndrome. Their blood samples were tested using ELISA for detection of 4 EBV specific antibodies (anti-VCA IgM and IgG, anti-EA-D IgG and anti-EBNA-1 IgG) and PCR for detection of EBV DNA. According to results of serology 42 patients had acute primary infection, 2 reactivation, 1 chronic active infection, 19 past infection, and 4 have been EBV seronegative. EBV DNA was detected in 17 patients (25%) and all of them were serologically defined as acutely infected. PCR was useful for resolving unclear serology results. Specific serology is the first step in diagnosis of IM, but PCR may serve as a useful additional diagnostic tool for clarifying serological dilemmas, reaching final diagnosis and defining status of the infection.

scholarly journals Maintenance of Serum Immunoglobulin G Antibodies to Epstein-Barr Virus (EBV) Nuclear Antigen 2 in Healthy Individuals from Different Age Groups in a Japanese Population with a High Childhood Incidence of Asymptomatic Primary EBV Infection

2004 ◽  
Vol 11 (1) ◽  
pp. 123-130 ◽  
Author(s):  
Shizuko Harada ◽  
Yoshio Kamata ◽  
Yasuyuki Ishii ◽  
Hiroyuki Eda ◽  
Ryo Kitamura ◽  
...  
Keyword(s):  
Immunoglobulin G ◽  
Epstein Barr Virus ◽  
Age Groups ◽  
Older Age ◽  
Nuclear Antigen ◽  
Age Group ◽  
Igg Antibodies ◽  
Healthy Individuals ◽  
Barr Virus ◽  
Epstein Barr

ABSTRACT Immunoglobulin G (IgG) antibodies to Epstein-Barr virus (EBV) nuclear antigens 2 and 1 (EBNA-2 and EBNA-1, respectively) were studied using sera from healthy individuals of a population with a high incidence of asymptomatic primary EBV infections during infancy or childhood in Japan. Two CHO-K1 cell lines expressing EBNA-2 and EBNA-1 were used for anticomplement and indirect immunofluorescence assays. The positivity rate for EBNA-2 IgG rose in the 1- to 2-year age group, increased and remained at a plateau (∼45%) between 3 and 29 years of age (3- to 4-, 5- to 9-, 10- to 14-, and 15- to 29-year age groups), and then reached 98% by age 40 (≥40-year age group). Both seropositivity for EBNA-1 and seropositivity for EBNAs in Raji cells (EBNA/Raji) were detected in the 1- to 2-year age group, remained high, and finally reached 100% by age 40. The geometric mean titer (GMT) of EBNA-2 IgG reached a plateau in the 5- to 9- and 10- to 14-year-old groups and remained elevated in the older age groups (15 to 29 and ≥40 years). The GMT of EBNA-1 IgGs increased to a plateau in the 1- to 2-year-old group and remained unchanged in the older age groups. The GMT of EBNA/Raji IgGs also reached a plateau in the 1- to 2-year-old group, remained level throughout the 3- to 14-year age groups, and decreased in the 15- to 29-year-olds. EBNA-2 IgGs emerged earlier than EBNA-1 IgGs in 8 of 10 patients with infectious mononucleosis, who were between 1 and 27 years old, and declined with time in three of eight cases. These results suggest that EBNA-2 IgG antibodies evoked in young children by asymptomatic primary EBV infections remain elevated throughout life, probably because of reactivation of latent and/or exogenous EBV superinfection.

scholarly journals Evaluation of Four Commercial Systems for the Diagnosis of Epstein-Barr Virus Primary Infections

2010 ◽  
Vol 18 (3) ◽  
pp. 444-448 ◽  
Author(s):  
Fernando de Ory ◽  
María Eulalia Guisasola ◽  
Juan Carlos Sanz ◽  
Isabel García-Bermejo
Keyword(s):  
Primary Infection ◽  
Epstein Barr Virus ◽  
Nuclear Antigen ◽  
Enzyme Linked Immunosorbent Assay ◽  
Igg Antibodies ◽  
Past Infection ◽  
Recent Infection ◽  
Barr Virus ◽  
Epstein Barr ◽  
Virus Capsid Antigen

ABSTRACTTo compare the performance of four diagnostic commercial systems for Epstein-Barr virus (EBV) serology (for IgM and IgG virus capsid antigen [VCA] and EBV nuclear antigen [EBNA] antibodies), a collection of 125 samples from clinically suspected infectious mononucleosis cases was studied. Indirect immunofluorescence (IIF) for VCA IgM and IgG antibodies and anticomplement immunofluorescence for EBNA antibodies (Meridian Bioscience Inc.) were used as reference methods. By these methods, the cases were classified EBV primary infection (presence of IgM to VCA or IgG to VCA in the absence of EBNA antibodies;n= 82), EBV past infection (presence of VCA IgG and EBNA antibodies in the absence of VCA IgM;n= 26), or no infection (negative for the three markers;n= 17). The following systems were tested: two chemiluminescent immunoassays (CLIAs; the Liason [CLIA-L; DiaSorin] and the Immulite 2000 [CLIA-I; Siemens]), immunofiltration (IF; All.Diag), and an enzyme-linked immunosorbent assay (ELISA; DiaSorin). In the IgM assays, sensitivities ranged from 67.1% (ELISA) to 92.2% (CLIA-L) and specificities ranged from 93.8% (CLIA-L) to 100% (IF). In the VCA IgG assays, sensitivities varied from 79.4% (IF) to 94.4% (CLIA-I) and specificities varied from 94.4% (IF and CLIA-L) to 100% (CLIA-I and ELISA). In EBNA assays, sensitivities ranged from 78.1% (IF) to 93.8% (CLIA-I) and specificities ranged from 32.3% (CLIA-L) to 91.4% (IF). In relation to EBV profiles, the corresponding figures for sensitivity (in detecting primary infection) for IF, CLIA-L, CLIA-I, and ELISA were 92.7%, 93.8%, 89%, and 89.6%, respectively, and those for specificity (to exclude primary recent infection) were 90.7%, 94.6%, 97.7%, and 95.2%, respectively. Although there were limitations in some individual markers, especially CLIA-L for EBNA IgG, the systems evaluated appear to be useful for diagnosis of EBV infection.

Epstein-Barr Virus Infection

1994 ◽  
Vol 15 (2) ◽  
pp. 63-68
Author(s):  
William A. Durbin ◽  
John L. Sullivan
Keyword(s):  
Epstein Barr Virus ◽  
Western Europe ◽  
Age Groups ◽  
The United States ◽  
The Philippines ◽  
Epstein Barr Virus Infection ◽  
Barr Virus ◽  
The Usa ◽  
Epstein Barr ◽  
Barr Virus Infection

Introduction Virtually all humans become infected with Epstein-Barr virus (EBV). The vast majority of these infections are inapparent, occur early in life, and are associated with lifelong latent infection and persistent shedding of virus. Epidemiology The prevalence of antibody to EBV has been determined in many age groups throughout the world. In developing and tropical areas, infection takes place early in life and is inapparent, with most children demonstrating antibody by age 6 years. Infection is believed to be related to hygiene and crowding as well as to cultural patterns that lead to exposure to saliva (eg, prechewing of food). In contrast, infection in Western Europe and the United States in childhood is less common, with only 35% to 50% of 5-year-olds demonstrating antibody. Infectious mononucleosis (IM) emerges as a significant clinical entity only in populations where a sizable percentage of young adults lack immunity to EBV. Thus, IM is unknown among college freshman in Thailand or the Philippines, virtually all of whom have antibody to EBV at the time of admission. On the other hand, in schools in the USA and England, where the susceptibility percentage is in the range of 35% to 50%, infection is seen commonly. In such university settings, approximately 12% of susceptible students become infected with EBV during the freshman year.

Case Report: Splenic Infarction in Infectious Mononucleosis due to Epstein–Barr Virus Infection

2021 ◽  
Author(s):  
Hiroaki Nishioka ◽  
Katsuma Hayashi ◽  
Hayato Shimizu
Keyword(s):  
Abdominal Pain ◽  
Infectious Mononucleosis ◽  
Epstein Barr Virus ◽  
Rare Complication ◽  
Clinical Syndrome ◽  
Splenic Infarction ◽  
Epstein Barr Virus Infection ◽  
Serological Tests ◽  
Barr Virus ◽  
Epstein Barr

Epstein–Barr virus (EBV) is the most common cause of infectious mononucleosis (IM) and IM is a clinical syndrome typically characterized by fever, pharyngitis, and cervical lymph node enlargement. We describe the case of a 19-year-old man with IM complicated by splenic infarction. The patient visited our hospital because of upper abdominal pain without a fever and sore throat. Abdominal computed tomography revealed a low-density area in the spleen, which indicated splenic infarction. The next day, he developed a fever. After diminishing abdominal pain and fever, he developed pharyngitis accompanied by fever. Acute EBV infection was confirmed by serological tests. The patient was successfully managed with no specific therapy. Splenic infarction is a rare complication of IM and this case showed that splenic infarction can precede a fever and pharyngitis.

Epstein-Barr virus VCA IgM and EBNA IgG antibodies titered by immunofluorescence in microplates

1982 ◽  
Vol 170 (4) ◽  
pp. 247-253 ◽  
Author(s):  
M. E. Lamy ◽  
A. M. Favart ◽  
M. F. Leclercq ◽  
M. Segas ◽  
M. Mendez ◽  
...  
Keyword(s):  
Epstein Barr Virus ◽  
Igg Antibodies ◽  
Barr Virus ◽  
Epstein Barr

scholarly journals A Systematic Study of Epstein-Barr Virus Serologic Assays Following Acute Infection

2002 ◽  
Vol 117 (1) ◽  
pp. 156-161 ◽  
Author(s):  
Thomas D. Rea ◽  
Rhoda L. Ashley ◽  
Joan E. Russo ◽  
Dedra S. Buchwald
Keyword(s):  
Systematic Study ◽  
Epstein Barr Virus ◽  
Acute Infection ◽  
Barr Virus ◽  
Epstein Barr

Epstein–Barr virus and regulatory T cells in Egyptian paediatric patients with acute B lymphoblastic leukaemia

2016 ◽  
Vol 70 (2) ◽  
pp. 120-125 ◽  
Author(s):  
Mohamed E Ateyah ◽  
Mona E Hashem ◽  
Mohamed Abdelsalam
Keyword(s):  
Lymphoblastic Leukaemia ◽  
Epstein Barr Virus ◽  
Acute Infection ◽  
Treg Cells ◽  
Control Group ◽  
Healthy Children ◽  
Barr Virus ◽  
Ebv Infection ◽  
High Incidence ◽  
Epstein Barr

ObjectiveAcute B lymphoblastic leukaemia (B-ALL) is the most common type of childhood malignancy worldwide but little is known of its origin. Recently, many studies showed both a high incidence of Epstein–Barr virus (EBV) infection and high levels of CD4+CD25+Foxp3+(Treg cells) in children with B-ALL. In our study, we investigated the possible relationship between EBV infection and the onset of B-ALL, and its relation to expression of CD4+, CD25high+Foxp3+ T regulatory cells.Subject and methodsWe analysed expression and mean fluorescence intensity (MFI) of Treg cells in peripheral blood of 45 children with B-ALL and in 40 apparently healthy children as a control, using flow cytometry. Serum anti-EBV viral capsid antigen (VCA) IgG, anti-EBV nuclear antigen (EBNA) IgG (for latent infection) and anti-EBV VCA IgM (for acute infection) were investigated using ELISA.ResultsAnalysis of the Treg cells population in patients and controls revealed that expression of CD4+ CD25high+ T lymphocytes was higher in patients than in controls (mean±SD 15.7±4.1 and 10.61±2.6 in patients and controls, respectively, and MFI of Foxp3 was 30.1±7.1 and 16.7±3.7 in patients and controls, respectively (p<0.001)). There was a high incidence of latent EBV infection in patients (31%) compared with controls (10%) while the incidence of acute infection was 12% in patients and 0% in the control group. To study the role of latent EBV infection in the pathogenesis of acute B-ALL, OR was calculated (OR=4.06, coefficient index 1.2–13.6).ConclusionsThese findings suggest a possible role for Treg cells and EBV in the pathogenesis of B-ALL. Further studies are needed on the possible mechanisms of tumour genesis related to Treg cells and EBV in children with B-ALL.

scholarly journals Performance of the Architect EBV Antibody Panel for Determination of Epstein-Barr Virus Infection Stage in Immunocompetent Adolescents and Young Adults with Clinical Suspicion of Infectious Mononucleosis

2014 ◽  
Vol 21 (6) ◽  
pp. 817-823 ◽  
Author(s):  
Alvaro Guerrero-Ramos ◽  
Mauli Patel ◽  
Kinjal Kadakia ◽  
Tanzina Haque
Keyword(s):  
Young Adults ◽  
Epstein Barr Virus ◽  
Clinical Suspicion ◽  
Adolescents And Young Adults ◽  
Sequential Testing ◽  
Igg Antibodies ◽  
Barr Virus ◽  
Antibody Panel ◽  
Epstein Barr ◽  
Testing Algorithm

ABSTRACTThe Architect EBV antibody panel is a new chemiluminescence immunoassay system used to determine the stage of Epstein-Barr virus (EBV) infection based on the detection of IgM and IgG antibodies to viral capsid antigen (VCA) and IgG antibodies against Epstein-Barr nuclear antigen 1 (EBNA-1). We evaluated its diagnostic accuracy in immunocompetent adolescents and young adults with clinical suspicion of infectious mononucleosis (IM) using the RecomLine EBV IgM and IgG immunoblots as the reference standard. In addition, the use of the antibody panel in a sequential testing algorithm based on initial EBNA-1 IgG analysis was assessed for cost-effectiveness. Finally, we investigated the degree of cross-reactivity of the VCA IgM marker during other primary viral infections that may present with an EBV IM-like picture. High sensitivity (98.3% [95% confidence interval {CI}, 90.7 to 99.7%]) and specificity (94.2% [95% CI, 87.9 to 97.8%]) were found after testing 162 precharacterized archived serum samples. There was perfect agreement between the use of the antibody panel in sequential and parallel testing algorithms, but substantial cost savings (23%) were obtained with the sequential strategy. A high rate of reactive VCA IgM results was found in primary cytomegalovirus (CMV) infections (60.7%). In summary, the Architect EBV antibody panel performs satisfactorily in the investigation of EBV IM in immunocompetent adolescents and young adults, and the application of an EBNA-1 IgG-based sequential testing algorithm is cost-effective in this diagnostic setting. Concomitant testing for CMV is strongly recommended to aid in the interpretation of EBV serological patterns.

Sign in / Sign up

Export Citation Format

Share Document